Marked elevation of the plasma PTX3 level was observed in the patients with NASH in comparison with the patients with non-NASH (p = 0.0021) and healthy control subjects (p = 0.0453). Here, PTX3 is linked to metabolic dysfunction-associated steatohepatitis.